CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset.

By S. López-Vergès, J. Milush, Suchitra Pandey, V. York, J. Arakawa-Hoyt, H. Pircher, P. Norris, D. Nixon, L. Lanier. Blood, 2010

757 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/c3e85dd8dbead8345bc457980789e35a946e9243

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Caligiuri
2. L. Lanier

In Oncology

1. L. Lanier

Citations in the corpus

• Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection (2011, background): “We and others reported that CD57 NK cells have a proliferation defect in vitro (31, 32), and after human stem cell transplantation (31).”
• The broad spectrum of human natural killer cell diversity (2017, methodology): “According to this developmental model, stage 4b cells are CD56CD16 CD57 cNK cells; stage 5 cells are ‘‘early’’ PB CD56CD16CD57 cNK cells; and stage 6 cells, which express the terminal differentiation-associated marker CD57 (Lopez-Vergès et al., 2010), are ‘‘late’’ PB CD56CD16CD57 cNK cells (Table 1;”